You are here

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
CASE REPORT
Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab
  1. Chee Hoou Loh1,2 and
  2. Geoffrey Herkes1,2
  1. 1 Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia
  2. 2 Department of Neurology, Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
  1. Correspondence to Dr Chee Hoou Loh, clemloh87{at}gmail.com

Abstract

We report the experience of reversing dabigatran prior to administering systemic thrombolysis for acute ischaemic cerebellar stroke, which was well tolerated with no haemorrhagic complications after thrombolysis. Given the increasingly common use of dabigatran for atrial fibrillation, the use of idarucizumab to reverse of dabigatran is a novel treatment that should be considered as an important adjunct to facilitate thrombolysis for ischaemic strokes and minimise haemorrhagic complications.

  • haematology (drugs and medicines)
  • neurology (drugs and medicines)
  • arrhythmias

https://doi.org/10.1136/bcr-2018-229128

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors CHL contributed to writing up of the manuscript, in consultation with GH.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Ethics approval Ethical approval has been sought from the Northern Sydney Local Health District Human Ethics Research Committee.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Patient consent for publication Next of kin consent obtained.